TScan Therapeutics
  • About
    • Our Company
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners

    About TScan

    TScan is a clinical-stage biotechnology company dedicated to creating life-changing T-cell therapies for patients by unleashing the potential of the human immune system.

  • Our Approach
    • Our Science
    • How We’re Different
    • Hematologic Malignancies
    • Solid Tumors
    • Autoimmunity

    Our Approach

    Our approach is based on the premise that conventional T cells provide the most effective way to fight cancer, and that by genetically reprogramming T cells with highly effective, naturally occurring T cell receptors (TCRs), we can harness the power of the human immune system to deliver life-changing therapies to patients.

  • Pipeline
    • Our Pipeline
    • Hematologic Malignancies Program
    • Solid Tumor Program

    Pipeline

    We are advancing a robust pipeline of TCR-T therapy candidates derived from our proprietary platform to treat patients with heme malignancies and solid tumors.

  • Platform
    • TargetScan
    • ReceptorScan
    • SafetyScan
    • T-Integrate Cell Engineering

    Platform

    Our proprietary platform is designed to discover anti-cancer TCRs from patients with exceptional responses to immunotherapy.

  • Publications
  • Investors and Media
  • For Patients
    • Hematologic Malignancies
    • Expanded Access Policy

    For Patients

    We are committed to bringing new immunotherapies to cancer patients and patients with other serious diseases.

  • Careers
  • About
    • Our Company
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners
  • Our Approach
    • Our Science
    • How We’re Different
    • Hematologic Malignancies
    • Solid Tumors
    • Autoimmunity
  • Pipeline
    • Our Pipeline
    • Hematologic Malignancies Program
    • Solid Tumor Program
  • Platform
    • TargetScan
    • ReceptorScan
    • SafetyScan
    • T-Integrate Cell Engineering
  • Publications
  • Investors and Media
  • For Patients
    • Hematologic Malignancies
    • Expanded Access Policy
  • Careers

Careers

TScan is building a dynamic team to translate the immense power of the immune system into new TCR-T therapies. We are looking for candidates with expertise across a variety of key functions in drug discovery and development to join our team. Click on the job postings below to learn more about our current opportunities.

All applicants should take care to avoid employment scams by bad actors posing as recruiters on behalf of potential employers, including TScan Therapeutics. Applicants are encouraged to confirm that the position for which they are applying is currently posted as an Open Position on our official website and to apply through TScan’s official web portal with ClearCompany. Be aware that all official TScan communications come from the TScan domain, ending in “tscan.com”, or through our ATS platform (tscan.therapeutics.careers@msg.clrco.com).

If you have been contacted about employment at TScan and would like to confirm that the contact is genuine, please contact the HR team at careers@tscan.com.

Current job openings

Principal Research Associate/Associate Scientist, Molecular Assembly (PRA02-001)

Waltham, MA

More Details

Clinical Trial Associate (CLIN30-0106)

Waltham, MA

More Details

Associate Director, Accounting (FIN44-002)

Waltham, MA

More Details

Senior Manager, Financial Planning & Analysis

Waltham, MA

More Details

“TCR-T therapy is cutting edge in oncology; it's thrilling to be collaborating with industry-leading academic and pharmaceutical partners to evolve patient care using TScan’s technology."

Sarah B.

“TScan is such an exciting place to work. Every employee, from CEO to scientist to office manager, feels like they are part of the team and making a difference.”

Sarah P.

"There is a palpable sense of excitement that we are making discoveries that will directly improve patient health."

Nancy N.

Interested in joining our team? Explore Careers

©2026 TScan Therapeutics
  • Contact
  • Cookie Settings
  • Privacy policy
  • Terms and conditions